Relevant bibliographies by topics / Cryoprecipitate transfusion

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Cryoprecipitate transfusion'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cryoprecipitate transfusion.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cryoprecipitate transfusion"

1

Nascimento, Barto, Jerrold H. Levy, Homer Tien, and Luis Teodoro Da Luz. "Cryoprecipitate transfusion in bleeding patients." CJEM 22, S2 (2020): S4—S11. http://dx.doi.org/10.1017/cem.2019.409.

Full text
Abstract:
ABSTRACTObjectivesThe management of acquired coagulopathy in multiple clinical settings frequently involves fibrinogen supplementation. Cryoprecipitate, a multidonor product, is widely used for the treatment of acquired hypofibrinogenemia following massive bleeding, but it has been associated with adverse events. We aimed to review the latest evidence on cryoprecipitate for treatment of bleeding.MethodsWe conducted a narrative review of current literature on cryoprecipitate therapy, describing its history, formulations and preparation, and recommended dosing. We also reviewed guideline recomme
APA, Harvard, Vancouver, ISO, and other styles
2

Curry, Nicola, and Henna Wong. "Cryoprecipitate transfusion: current perspectives." International Journal of Clinical Transfusion Medicine Volume 4 (September 2016): 89–97. http://dx.doi.org/10.2147/ijctm.s99042.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sandhu, Manpreet K., Trishala Agrawal, Maya Shah, and Alice J. Cohen. "Overuse of Cryoprecipitate: A Chronic Condition,." Blood 118, no. 21 (2011): 4212. http://dx.doi.org/10.1182/blood.v118.21.4212.4212.

Full text
Abstract:
Abstract Abstract 4212 Background: Literature has revealed that there is considerable inappropriate use of blood products including cryoprecipitate (cryo). Appropriate indications for cryo use according to American Association of Blood Banks (AABB) guidelines include bleeding due to hypofibrinogenemia (fibrinogen level < 100mg/dl) or dysfibrinogenemia, factor XIII deficiency, bleeding associated with Hemophilia A or von Willebrand disease (when appropriate factor concentrates are not available) and uremic bleeding (DDAVP preferred). To determine appropriateness of use of cryo at Newark Beth
APA, Harvard, Vancouver, ISO, and other styles
4

Nigam, A., A. Prakash, and P. Saxena. "Blood Transfusion in Obstetrics." Kathmandu University Medical Journal 11, no. 4 (2015): 355–59. http://dx.doi.org/10.3126/kumj.v11i4.13484.

Full text
Abstract:
Transfusion of blood and blood components is a common practice in obstetric wards but it is not without risk. The incidence of transfusion reactions varies from 4 in every hundred transfusions for non-haemolytic reactions to one in every 40,000 for haemolytic transfusion reactions. The physiological basis of blood transfusion is outlined in this article. Most of the donated blood is processed into components: packed red cells (PRBCs), platelets, and fresh frozen plasma (FFP) or cryoprecipitate. Various alternatives to blood transfusion exist and include autotransfusion, pre-autologous blood st
APA, Harvard, Vancouver, ISO, and other styles
5

Kruse, Robert L., Melissa Neally, Brian C. Cho, et al. "Cryoprecipitate Utilization Patterns Observed With a Required Prospective Approval Process vs Electronic Dosing Guidance." American Journal of Clinical Pathology 154, no. 3 (2020): 362–68. http://dx.doi.org/10.1093/ajcp/aqaa042.

Full text
Abstract:
Abstract Objectives We evaluated the impact of electronic medical record (EMR)–guided pooled cryoprecipitate dosing vs our previous practice of requiring transfusion medicine (TM) resident approval for every cryoprecipitate transfusion. Methods At our hospital, cryoprecipitate pooled from five donors is dosed for adult patients, while single-donor cryoprecipitate is dosed for pediatric patients (defined as patients <50 kg in weight). EMR-based dosing guidance replaced a previously required TM consultation when cryoprecipitate pools were ordered, but a consultation remained required for
APA, Harvard, Vancouver, ISO, and other styles
6

Castillo, R., J. Monteagudo, G. Escolar, A. Ordinas, M. Magallon, and J. Martin Villar. "Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients." Blood 77, no. 9 (1991): 1901–5. http://dx.doi.org/10.1182/blood.v77.9.1901.1901.

Full text
Abstract:
Abstract Platelet von Willebrand factor (vWF) has been suggested to play an important role in the hemostatic process. Clinical and experimental data indicate that bleeding time (BT) and platelet-vessel wall interaction cannot be normalized unless the defect of platelet vWF is also corrected. We have examined the effect of normal platelet concentrate transfusion 1 hour after cryoprecipitate infusion in five type III von Willebrand disease (vWD) patients. The cryoprecipitate infusion attained normal circulating levels of ristocetin cofactor, vWF antigen, and factor VIII activity. In two patients
APA, Harvard, Vancouver, ISO, and other styles
7

Castillo, R., J. Monteagudo, G. Escolar, A. Ordinas, M. Magallon, and J. Martin Villar. "Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients." Blood 77, no. 9 (1991): 1901–5. http://dx.doi.org/10.1182/blood.v77.9.1901.bloodjournal7791901.

Full text
Abstract:
Platelet von Willebrand factor (vWF) has been suggested to play an important role in the hemostatic process. Clinical and experimental data indicate that bleeding time (BT) and platelet-vessel wall interaction cannot be normalized unless the defect of platelet vWF is also corrected. We have examined the effect of normal platelet concentrate transfusion 1 hour after cryoprecipitate infusion in five type III von Willebrand disease (vWD) patients. The cryoprecipitate infusion attained normal circulating levels of ristocetin cofactor, vWF antigen, and factor VIII activity. In two patients, cryopre
APA, Harvard, Vancouver, ISO, and other styles
8

Karim, Shanaz, Ehteshamul Hoque, Md Mazharul Hoque, Syeda Masooma Rahman, and Kashfia Islam. "Blood Component Therapy." Anwer Khan Modern Medical College Journal 9, no. 2 (2018): 142–47. http://dx.doi.org/10.3329/akmmcj.v9i2.39211.

Full text
Abstract:
Transfusion medicine has undergone advancements since its initiation in the early 20th century. One of these was the discovery that blood can be divided into individual components and delivered separately. Today, blood transfusions nearly always consist of the ad-ministration of 1 or more components of blood. Whole blood transfusion is now limited to situations involving massive resuscitation (trauma ) The most familiar cellular components include packed red blood cells (PRBC), washed PRBC, leukoreduced PRBC and pooled or aphaeresis platelets. Plasma products such as FFP or cryoprecipitate, an
APA, Harvard, Vancouver, ISO, and other styles
9

Serei, Virian, Cecilia Wong, and Grace Tenorio. "Cryoprecipitate Usage and Cost at a Tertiary Care Hospital Between 2010 and 2017." American Journal of Clinical Pathology 152, Supplement_1 (2019): S154. http://dx.doi.org/10.1093/ajcp/aqz131.008.

Full text
Abstract:
Abstract Introduction Cryoprecipitate (CRYO), a blood product prepared from FFP, is rich in fibrinogen, von Willebrand’s factor, and factors VIII and XIII. ​The major indication for CRYO transfusion is fibrinogen deficiency with increased risk of bleeding when fibrinogen is <100 mg/dL, a transfusion trigger rarely followed by the house staff or other clinicians. To limit wastage, Transfusion Services issue them as pools of five individual CRYO units. The use of CRYO at Robert Wood Johnson University Hospital (RWJUH) has significantly risen since 2010, so we conducted a study to identify the
APA, Harvard, Vancouver, ISO, and other styles
10

Ho, Debbie, Erick Chan, Don Campbell, et al. "Targeted cryoprecipitate transfusion in severe traumatic haemorrhage." Injury 51, no. 9 (2020): 1949–55. http://dx.doi.org/10.1016/j.injury.2020.05.044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cryoprecipitate transfusion"

1

Nascimento, Bartolomeu Jr. "Cryoprecipitate Transfusion: Assessing Appropriateness and Dosing in Trauma." Thesis, 2012. http://hdl.handle.net/1807/32611.

Full text
Abstract:
Cryoprecipitate is commonly used outside guidelines. In trauma, the appropriate cryoprecipitate dose and its impact on plasma fibrinogen levels are unclear. This retrospective study aims to evaluate: (1) the appropriateness of cryoprecipitate transfusion in trauma; and (2) the plasma fibrinogen response to cryoprecipitate transfusion during massive transfusion in trauma. Fibrinogen levels of < 1.0 g/L within 2 and 6 hours of cryoprecipitate transfusion were used for assessing appropriateness. Out of 394 events, 238 (60%) and 259 (66%) were considered appropriate using 2 and 6 hour criteria,
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Cryoprecipitate transfusion"

1

Hatfield, Anthea. The bleeding patient. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199666041.003.0026.

Full text
Abstract:
Part one of this chapter tells you about the physiology of blood and oxygen supply, about anaemia and tissue hypoxia, and the physiology of coagulation. Drugs that interfere with clotting are discussed. Bleeding, coagulation, and platelet disorders are covered as well as disseminated intravascular coagulation. Part two is concerned with bleeding in the recovery room: how to cope with rapid blood loss, managing ongoing blood loss, and how to use clotting profiles to guide treatment. There is also a section covering blood transfusion, blood groups and typing. Massive blood transfusion is clearly
APA, Harvard, Vancouver, ISO, and other styles
2

Spinella, Philip C., and Jeffrey J. Bednarski. Hematology and Oncology. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199918027.003.0013.

Full text
Abstract:
Coagulopathy, thrombosis, and other hematological abnormalities are common in the pediatric intensive care unit . Current guidelines recommend red blood cell transfusion for a hemoglobin concentration less than 7 g/dL in critically ill, hemodynamically stable patients; platelets for a concentration less than 10,000 in nonbleeding patients; and cryoprecipitate in bleeding patients for fibrinogen values less than 100 to 150 mg/dL. Massive transfusion protocols that push blood products to the bedside are more practical than reactive protocols. Transfusion reactions include transfusion-associated
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Cryoprecipitate transfusion"

1

Callum, Jeannie L., and Bartolomeu Nascimento. "Cryoprecipitate Transfusion." In Trauma Induced Coagulopathy. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-28308-1_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nascimento, Barto, and Sandro Rizoli. "Cryoprecipitate Transfusion in Trauma." In Encyclopedia of Trauma Care. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-29613-0_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stanworth, Simon J., and Alan T. Tinmouth. "Plasma and cryoprecipitate for transfusion." In Rossi's Principles of Transfusion Medicine. John Wiley & Sons, Ltd., 2016. http://dx.doi.org/10.1002/9781119013020.ch26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Davenport, Ross A., Laura Green, and Karim Brohi. "Cryoprecipitate/Fibrinogen Concentrate Transfusions." In Trauma Induced Coagulopathy. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-53606-0_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sharma, Aradhna. "Cryoprecipitate." In Transfusion Update. Jaypee Brothers Medical Publishers (P) Ltd., 2015. http://dx.doi.org/10.5005/jp/books/12449_50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shaz, Beth H., and Christopher D. Hillyer. "Cryoprecipitate." In Transfusion Medicine and Hemostasis. Elsevier, 2009. http://dx.doi.org/10.1016/b978-0-12-374432-6.00031-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Cryoprecipitate (CRYO) Transfusion." In Encyclopedia of Trauma Care. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-29613-0_100424.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shaz, Beth H., and Christopher D. Hillyer. "Cryoprecipitate and Fibrinogen Concentrates." In Transfusion Medicine and Hemostasis. Elsevier, 2013. http://dx.doi.org/10.1016/b978-0-12-397164-7.00034-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bucur, Silvana Z., and Christopher D. Hillyer. "Cryoprecipitate and Related Products." In Handbook of Transfusion Medicine. Elsevier, 2001. http://dx.doi.org/10.1016/b978-012348775-9/50057-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sachais, Bruce S., and Eric Senaldi. "Cryoprecipitate and Fibrinogen Concentrates." In Transfusion Medicine and Hemostasis. Elsevier, 2019. http://dx.doi.org/10.1016/b978-0-12-813726-0.00036-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cryoprecipitate transfusion"

1

Nichols, W. L., T. M. Habermann, S. E. Kaese, and E. J. W. Bowie. "GLANZMANN'S THROMBASTHENIA: HEMOSTATIC EFFECTIVENESS OF PLASMA CRYOPRECIPITATE TRANSFUSION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644744.

Full text
Abstract:
A 39-year-old 75 kg man with Type I Glanzmann's thrombasthenia developed recurring severe therapy-refractory nosebleeds, associated with nasal septal deformity, synechial scarring, and previous radiotherapy. During a 21 month period he required 16 hospitalizations for treatment of severe epistaxis. At initial hospitalization it was observed that his epistaxis ceased shortly after transfusion of 10 bags (units) of plasma cryoprecipitate (cryo), although transfusion with HLA-matched apheresis platelets from 3 donors, and topical therapy (cautery, packing), had been ineffective. Serum anti-platel
APA, Harvard, Vancouver, ISO, and other styles
2

Vigano, G., E. Marchesi, G. Remuzzi, and G. Mecca. "CONJUGATED ESTROGENS (CE) TO REDUCE BLEEDING IN UREMICS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643077.

Full text
Abstract:
Bleeding is a major complication of uremia. Both cryoprecipitate and desmopressin favourably infuence clinical bleeding, but the former carries the risk of transmitting blood-borne infectious diseases and both have a short duration of action. We recently demonstrated in a controlled study that CE effectively shortened bleeding time (BT) (the best available marker of clinical bleeding) in uremics. The effect of CE on BT is long lasting. Thus CE might represent an alternative to cryoprecipitate or desmopressin when long-lasting hemostatic” competence is required. In the present study we followed
APA, Harvard, Vancouver, ISO, and other styles
3

Baumgartner, C., B. A. Perret, E. Meili, M. Furlan, H. Friedli, and J. J. Morgen-thaler. "NORMAL IN VIVO KINETICS OF FACTOR VIII (F VIII) AND FACTOR IX (F IX) TREATED WITH TRI (N-BUIYL) PHOSPHATE (TNBP) AND TWEEN 80 FOR INACTIVATION OF VIRUSES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644068.

Full text
Abstract:
Heat treatment has been cxxnmonly used for the sterilisation of coagulation factor concentrates. This causes, however, considerable loss of coagulation factor activity? therefore alternative methods have been developed. Two new virus-inactivated coagulation factor preparations were recently introduced by our institution. Their manufacturing procedure includes a lipid solvent extraction step: The cryoprecipitate (F VIII preparation) or the first DEAE eluate (F IX preparation) is incubated with 0.3 % TNBP and 1 % Tveen 80 at 24°C for at least 12 hours. (Horowitz, Transfusion 25 : 516-522, 1985).
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cryoprecipitate transfusion' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography